Zhejiang Jianfeng Pharmaceutical Co., Ltd was established on December 31, 1998. It is a wholly-owned subsidiary of Zhejiang Jianfeng Group Co. Ltd. (stock code: 600668). The company has a registered capital of 198 million yuan and it has more than 800 employees. At the end of 2017, the company's total assets are 1.196 billion yuan and sales income is 1.333 billion yuan, and profits and taxes are 144 million yuan.

The company has 10 wholly-owned, holding and shareholding pharmaceutical production enterprises, 6 pharmaceutical business enterprises, 5 national post-doctoral scientific research stations, 1 provincial-level academician expert workstation, 44 international and domestic pharmaceutical invention patents, and the dominant product market ( the top 3 rankings.)  The company has been rated as national high-tech enterprise, national intellectual property model enterprise, innovative model enterprise in Zhejiang Province, and patent demonstration enterprise in Zhejiang Province.  The “Jianfeng” trademark is recognized as a famous Chinese trademark.

The company adheres to the enterprise spirit of " base on jianfengzhi, major in quality medicine ", and pursues the business philosophy of "making science and technology to make health", and insists on developing high-tech, high value-added chemical raw materials and new chemical and Chinese patent preparations. The direction of new drug research and development with projects and funds as the link. Then it has achieved high quality development. Cooperated with German research institutes, The company has established Sino-German joint venture Zhejiang Erying Pharmaceutical Co, Ltd., specializing in R&D, production and management of infant and young children's drugs; participating in Beijing Huibaoyuan Biotechnology Co., Ltd., cooperating to develop a new class of anti-tumor drugs in the country, expanding Pharmaceutical market; holding Shanghai Beika Pharmaceutical Technology Co., Ltd., specializing in the research and development, production and operation of pharmaceutical and chemical intermediates, pharmaceutical raw materials, and expanding the international market for high-end pharmaceutical raw materials and intermediates. The company will adhere to scientific and technological innovation and promote the integration of production, education and research with technology and products as the carrier. The company will continuously improve the company's management level and brand influence and take the international development road.

Corporate reputation：

In 1999, it was awarded the title of “Top Ten Enterprises in Zhejiang Pharmaceutical Industry”
In 2000, it was awarded the title of "Top 20 Enterprises in Zhejiang Pharmaceutical Industry"
In 2001, it was awarded the title of "Top Ten Enterprises in Zhejiang Pharmaceutical Industry"
In 2002, it was awarded the title of "Top Ten Enterprises in Zhejiang Pharmaceutical Industry"
In 2003, it was awarded the title of "Top Ten Enterprises in Zhejiang Pharmaceutical Industry"
Ranked 49th in the national pharmaceutical industry enterprises in 2003
In 2003, it was awarded the title of “Contract-honoring and Promise-keeping Unit”
In 2003, he was awarded "Zhejiang High-tech Enterprise"
In 2003, “Leo” was recognized as “National High-tech Industrialization Demonstration Project”
In 2004, "Leo" was awarded the title of "National Key New Product"
In 2005, he was awarded the "National High-Tech Enterprise"